

AXA 1Q18 conference call Transcript

**May 4, 2018
09.00 Paris time**



This document is the transcript of the 1Q18 conference call held on May 4, 2018. The podcast of this presentation is available on <https://www.axa.com/en/investor/earnings-presentation>. In the event of any inconsistency between the transcript and the podcast, the podcast will prevail. In addition, the following transcript is unedited, and statements and figures therein are accordingly in all cases subject to those set forth in AXA's most recently published quarterly or annual results.

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA's actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 - "Risk factors and risk management" of AXA's Registration Document for the year ended December 31, 2017, for a description of certain important factors, risks and uncertainties that may affect AXA's business and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.

In addition, this Press Release refers to certain non-GAAP financial measures, or alternative performance measures, used by management in analyzing AXA's operating trends, financial performance and financial position and providing investors with additional information that management believes to be useful and relevant regarding AXA's results. These alternative performance measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group's consolidated financial statements and related notes prepared in accordance with IFRS. The abovementioned and other non-GAAP financial measures used in this Press Release are defined in the Glossary set forth in AXA's 2017 Activity Report (pp. 70-77).

1Q18 CONFERENCE CALL TRANSCRIPT

Andrew Wallace-Barnett, Head of Investor Relations, AXA

Okay. Good morning, everybody. This is Andrew. Welcome to the AXA Conference Call on our Activity Indicators for the first quarter of 2018. I am pleased to welcome Gérald Harlin, Deputy CEO and Group CFO of AXA, who will be taking you through the highlights of the first quarter, and be very happy afterwards to take your questions. Gérald, I hand over to you.

Gérald Harlin, Deputy CEO and Group CFO, AXA

Thank you, Andrew. So, hello and good morning to all. Thanks a lot for joining this call.

AXA has delivered a strong operating performance in the first quarter of 2018. We are growing our topline with total gross revenues growing by 2% at the Group level. Our APE was up 5% and our NBV was also up 5%.

This overall growth was supported by a continued focus towards our preferred segments: Health revenues were up 7%, with growth in all geographies, Protection APE was up 9% and P&C commercial lines revenues were up 2%. We also reported a Solvency II increase of 16 points from full-year 2017 to 221%.

Let me now take you into the details of each of our geographies and starting first with AXA France.

AXA France had an excellent first quarter with revenues increasing by 8%. APE was up 20% from higher sales across product lines with particularly strong growth in Health, plus 39%, coming from growth in both individual and international group business. Protection was up 11% from strong sales in group Protection business and Unit-Linked plus 7%. The Unit-Linked share of Individual Savings business was 43% as compared to French market at 33%. In P&C, we saw growth in commercial lines, but continue to face strong market competition in personal lines, particularly in Motor.

In Europe now, total revenues grew by 1% as we continued to see the successful business repositioning towards preferred segments. APE in Europe increased by 9% with strong growth in Protection, plus 17%, and Unit-Linked, 32%. The Protection APE in Europe growth was mainly driven by higher sales of semi-autonomous solutions in Switzerland, in line with our strategy. With the transformation of our in-force book announced last month, we will become the largest provider of semi-autonomous solution for SMEs in Switzerland. Unit-Linked APE growth in Europe was driven by Italy following a continued recovery in AXA MPS and strong sales in agency channel and by Spain due to the repositioning of away from GA savings towards Unit-Linked. P&C revenues in Europe increased by 2% and Health revenues increased by 3%.

Moving now to Asia. We continued our focus on improving business mix in China, moving away from short-term single premium products and towards regular premium. This resulted in a 45% decline in APE for China, contributing significantly to the overall increase in NBV margin for Asia, increasing 4 points to 62%. Indeed, the NBV margin in China went up from 27% to 56%. In Japan, APE grew by 4%, driven by the launch of the new

Protection product. And in the rest of Asia, APE was 7% with growth in all countries. The Philippines and Indonesia were up 37% and 9% respectively, driven by growth in Protection. Thailand was up 6% from a higher Unit-Linked sales, and Hong Kong was up 3%, with the successful launch of the new G/A Savings product and higher Health sales.

In the US, Life & Savings APE was up 3% from higher Mutual Fund advisory sales, partly offset by non-repeat of the 1Q17 strong sales of non-GMxB Variable Annuity, in anticipation of the implementation of the US Department of Labor rule. AB revenues were up by 13%, with higher average AuM mainly due to positive market developments in 2017 and improved business mix.

In International, revenues were up 3%, mainly driven by a good performance in Health, especially in Mexico. In AXA IM, revenues were up 1%, linked to higher average assets under management. We also had strong net inflows in our AXA IM Asian JVs and third-party clients amounting to Euro 7 billion.

Now, moving on to Solvency II ratio which, as I mentioned earlier, was up 16 points. This increase was driven by three main factors: strong operating return net of accrued dividends, second, a Euro 2 billion Tier-2 debt issuance in March to finance part of the XL acquisition, plus 7 points, and last, management action to reduce equity market risk around 8 points. This is partly offset by EIOPA changes in UFR and on the reference portfolio weights for the volatility adjuster. At 221%, the Group is in a very strong position.

So, to conclude, a strong quarter with top-line growth for Group; an excellent quarter in France, continued growth and shift in business mix in Europe and in Asia, and net inflows in AXA IM. All this with a very strong capital position and Solvency II ratio at 221%.

So, I am now ready to take your questions.

Q&A SESSION

Operator Ladies and gentlemen, we are entering the question and answer session. [Operator Instructions] We have a first question from Mr. Peter Eliot from Kepler Cheuvreux. Sir, please go ahead.

Peter Eliot | Kepler Cheuvreux Thank you very much. I had two questions on the solvency, please.

I guess the first one in the – the ratio came in quite a distance ahead of all of our expectations. So, I was wondering if you could just talk us through the drivers, quantify the drivers in a bit more detail and you gave the 7 points from the debt issuance and the 8 points from the de-risking, but I was wondering if you could quantify the other moving parts, and in particular, the operating profit and I mean given that you have guided for 3% points on the UFR drag and I am guessing that was maybe a bit lighter and maybe we can expect a lower drag in future years as well.

And secondly, at the full year results, you indicated that there was a link between the position you were within your solvency target range and the position you were in the payout ratio range. I am just wondering if you can comment on whether there is any reasons behind the recent jump in solvency ratio or, indeed, the announcements to the XL Group acquisition which might change our perception of that link? Thank you very much.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay, Peter. So, first of all, so let me go through the 16 points increase in Solvency II ratio.

So, first, we have a strong operating return. You remember that we told you that we were expecting between 15 and 20 points. And here, obviously, we are at the high-end of the range at 20% equivalent. So, that is on a yearly basis.

Second, that is the Euro 2 billion Tier 2 debt issuance. You notice that on the 5th of March when we announced the XL acquisition, we said that we would raise Euro 3 billion of Tier-2 debt, we already did Euro 2 billion under excellent conditions because we did it at 3.25% pre-tax, which means that post-tax cost will be ca. 2% only.

Then we have some management action to reduce our equity risks which led to 8 points positive impact. Maybe a few words about this. You know that we constantly seek to optimize the return on SCR. So, indeed, we reduced our exposure to equity rates through derivatives by purchasing put options. We capture the benefit from the relatively low level of volatility, while we retain the upward equity movements. So, that's mainly the reason why we did it. And as you know, we have 4%¹ of equity exposure, which is roughly Euro 22 billion, and we did it on roughly 20% of our portfolio. So, that answers your first question.

The second is the solvency target range. So, it's quite obvious that we are at the top end of the target range, but you can imagine that the acquisition of XL will put us back, I would say, comfortably within the 190% to 200%.

¹ During the call, equity exposure was mentioned to be at "44%", instead of "4%". This has been corrected here in the transcript.

So, I am quite comfortable to say that we will be within this range. Whether it changes something on the payout ratio, there is no direct link with our payout ratio but I remind you that our payout ratio, we moved from 48% to 49% this year. And we are not at the top of the range because the range still remains between 45% and 55%.

Peter Eliot | Kepler Cheuvreux Thanks so much. Maybe just to come back quickly on the first question, I was just wondering if you could comment on that the UFR drag in particular and what we should expect going forward. And also the 20 points you mentioned, I mean, I am just assuming that translates into 2.5 points of net for the quarter.

Gérald Harlin | Deputy CEO and Group CFO, AXA Yes, agreed. That is roughly 2.5 points net. About the UFR. We have a reduction of 15 basis points, which means that we are moving to 4.05%. And the UFR represents roughly minus 2 points in term of solvency. And you know also that we have the reference portfolio. You know that the reference portfolio is used in order to calculate the volatility adjuster. It is on a recurrent basis it is reviewed and we had a negative impact of minus 3 points².

Peter Eliot | Kepler Cheuvreux Okay. Thank you very much.

Operator Okay. Next question from Farooq Hanif from Credit Suisse. Sir, please go ahead.

Farooq Hanif | Credit Suisse Hi, there. Good morning. I just want to go back to your comment about being comfortable about the 190% to 200% range post the XL deal. So, when you first set that target, presumably you did not know what the impact of equity hedging would be. So, you are 8 points better on that basis following the hedging. So, when you say comfortably, does that really imply that you are bullish about the range? That is my sort of questions for your comment.

Second point is, are there any major earnings implications of the equity de-risking that you have done?

And third question is – actually, I forgot the third question, just those two. Thanks.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, Farooq, about your first question, you know that taking into – first of all, it is a measure that has been taken – this hedging has been taken just in line with the present market conditions. So, first of all, we consider that whatever happens, it is sound capital management. At the time we announced the deal, at the beginning of March, we knew that we would make some equity hedges because it made a lot of sense in terms of capital management. So, you cannot consider that it is 8 points on top. And so, you can expect, we will be within the range 190% to 200%, which is a quite a sound range, meaning that I remind you that, at the end of 2016, we were at 197%. So, that means that we remain actually very strong. We will remain with this transaction. And taking into account the IPO of the US business, we will be at a very strong solvency level.

² The minus ca. 2-3 points impact on the Solvency II ratio corresponds to the combined effect of changes in the UFR and the EIOPA reference portfolio weights, as was clarified later during the call (p. 12 of the transcript).

You said the question about the impact of this hedging on earnings. I just would like to remind you that we ended up 2017 with a quite strong level of equity unrealized gains because we realized a level of Euro 2.5 billion, so meaning that – and that is also the reason why it made a lot of sense to move in this direction because for a limited cost, it is, again, it is an excellent return on capital. So, no problem because you know that we are realizing some capital gains. I do not expect that realization of capital gains will be lower due to this hedging, not at all. And so, that is why, again, it is a good management of capital.

Farooq Hanif | Credit Suisse Okay. Thank you very much.

Operator Okay. Next question from Andrew Sinclair from Bank of America Merrill Lynch. Sir, please go ahead.

Andrew Sinclair | Bank of America Merrill Lynch Thanks. Morning everyone. Just wondering if you could give us – I just have three questions.

Firstly, Asia sales look maybe a little bit weaker, excuse me, than expected this quarter. Hong Kong Protection sales, in particular, down 25% year-on-year seemed a little bit disappointing, just wonder if you can let us know what has happened here.

Secondly, I just wonder if you could give us an update on thoughts on recent DOL development which looked somewhat more positive for the industry.

And thirdly, just wondered if you are able to give any commentary on XL's results, in particular, the shift in portfolio mix, increased use of outward reinsurance on XL's reinsurance segment is that kind of in line of what AXA is proposing to do going forwards. Thanks.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, what I can say about Hong Kong, so that means that as far as Hong Kong, as you can see in the document in the appendix, APE in Hong Kong grew by 3%. So, we had plus 15% in Health which is quite good, and we did it mostly on group contracts which is absolutely in line with our strategy. At the same time, we had – in Protection, we have some declines that – no specific worry on this time. So, that means that we have the business mix where we did less Protection, more Health this quarter. By definition, it has an impact on the NBV margin, but at the same time, I should remind you that we still have a very sound and high NBV margin at 44% in Hong Kong. So, it is quite obvious that we have a competitive market over there. But you remember that we have to do the right balance, to strike the right balance between volume and profitability. We had a very strong profitability at level around 60% up to now and especially last year. We are back at a level of 40%-44% which we consider this good and which allows us to be positive and you can expect us still remain in positive territory in Hong Kong this year. So, that is for the first – for your first question.

About the second one, about DOL. So, I believe that, if I could say that the situation in the US, that we have an APE growth of 3%, but this APE growth would have been higher if the reference would not be Q1 last year, why? Because in Q1 last year, it was just before the DOL and, at that time, we had strong sales in anticipation for DOL. So, that means and to answer more precisely your question, that the underlying trend is above 3%, which is good.

And second, it means that, indeed, the DOL impacts are quite good with the recent events, which means that the DOL impact will be much weaker than what we could fear some time ago.

About XL...

Andrew Sinclair | Bank of America Merrill Lynch Sorry, Gérald, just before you move on, I was more looking for a commentary on the announcements over the last few weeks from regulators and government in the US suggesting maybe DOL is being ruled back to some extent? I just wondered if you could give any thoughts on that.

Gérald Harlin | Deputy CEO and Group CFO, AXA Well, I believe that I cannot be more precise. It is a good decision. It should be a good outcome. But I do not want to anticipate it, that is only my point. So, yes, it is good. So, it is upside for us. But how far it will translate, how quickly it will translate into our figures, I cannot be more precise. That's my only – that's a limit. But, yes, it goes in the right direction. But I do not want to oversell it, and that is why let's wait. But it is good for the US business. And at the time, we do the IPO, it is a good news.

Andrew Sinclair | Bank of America Merrill Lynch Sure.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, about XL. So, I would say that XL, first of all, I would like to say that we are still legally constrained in what we can publicly discuss about XL. You know that you can refer to their press release and their earnings deck.

What I can tell you is that XL published solid Q1 results, and they were in line with their expectations. So, I would say – no surprise. What I could say that topline grew at constant FX by 4%, which is a good news. It is partly supported, and this is important, by an increase in both insurance and reinsurance plus 3.3% increase in rates in insurance, plus 4.3% increase in rates in reinsurance. I just would like to add one technical point. So, the effect of price increase on earnings could not be visible in Q1. Why? Because you know that the earnings are coming from earned premiums. And so, that means that it will take time before this rate increase will flow into earnings, but that is a good news.

Second, I could say that the management of XL is taking some strategic initiatives to shift the portfolio mix toward lower volatility and move to higher CAT protection. This was absolutely in line with what we announced. And I would say that, just to conclude that – from their press release, significant improvement. You saw a significant improvement in the operating net income in Q1. And again, it was in line with management expectation. So that is what I can tell you, so it is no surprise, I would say.

Andrew Sinclair | Bank of America Merrill Lynch Okay thanks.

Operator Okay. Next question from Mr. Nick Holmes from Société Générale. Sir, please go ahead.

Nick Holmes | Société Générale Hi there. Thank you very much. Just one question. I wondered how concerned are you about the French banks saying that they want to write more P&C business in France. Is this much of a threat? Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA Hello Nick, good morning. So, I would say that it is not new. So, it is still – we have a quite competitive environment, and you can see it in the press release. In Motor in France, we had also – we had some positive price increases. Nevertheless, we are in, Personal Motor, we were at minus 4%. So, yes, there is a competitive environment. I believe and I do not expect that we will stay at such a level of minus 4% and we are taking some measures in order, and it is not a decrease in our profitability, it is more segmentation, some incentive that could be given to the sales force, which means that we can expect to have an improvement in the course of the year.

But nevertheless, it is obvious with the *Loi Hamon* we have more competition in France at the same time, I remind you, that we have a strong and a good and sound profitability throughout P&C in France, whatever the products, including Motor and Individual Motor which means that – and which is not the case of the whole market. I remind you that the whole market is far above 100%, which is not our case. So, nevertheless, in the end you know, I am quite happy and proud with the global Group plus 2% in revenue, which means that we can be extremely profitable going on improving our profitability while growing the topline.

Nick Holmes | Société Générale That is very clear. Thank you very much.

Operator Thank you. So, next question from Oliver Steel from Deutsche Bank. Sir, please go ahead.

Oliver Steel | Deutsche Bank Morning. Thank you for taking the call. I have three questions.

The first is – just coming back to the equity hedging. How long – I mean, you said that it was a reaction to present market conditions. How long is the hedging actually in place for? And perhaps linked to that, you could give us the new equity sensitivity both upwards and downwards on your solvency.

Secondly, I mean you produced some extremely good growth numbers in the French Life & Savings business and Health. How much of that – I mean that feels as if it is a bit of a sea change relative to – I mean even some pretty good numbers last year. I am just wondering how sustainable those sort of growth numbers are.

And then, the third question because I did not talk to you at the time. You released or you are going to release something like CHF 2.5 billion of capital, I think, from the Swiss Life business. But you have also, I think you have also – I think you have also released an equivalent amount of reserves and I am just wondering what the net solvency effect will be from that at the Group level.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Good morning, Oliver. So first, how long, your first question is the equity hedging, how long. So, what we did is we did it quite long, two years equity hedging. Why two years? Because in order to benefit from the solvency, we should have quite some visibility and we should have at least a one year visibility in order to have the full benefit in term of solvency. So, to make it clear, it is more rational to do long-term, long-term hedging. What is the new equity sensitivity? We can calculate it. You know, I give you just a quick guideline. As I told you, we hedged 20% and it is 20% which had been hedged, so, that means that you could imagine that, more or less, you can reduce by 20% the sensitivity, maybe slightly higher, but that is what you can keep as a good guideline.

The French, your second question, was about the French Life & Savings. So, yes, we had a very good start with some contracts and some good contracts – international contracts in Health, it is a good start. We still are expecting to have a strong growth this year in France. Nevertheless, I just wanted – and sorry to make this digression, Oliver, but I just wanted to highlight one point. On the APE side, we are posting plus 5%, okay? But look at China, if I exclude China, we would have been at plus 8%, which confirms this very strong start. And the strong expectation and it is not only a strong start. We hope that this year will be good in term of Life-like growth.

As far as Swiss business is concerned, yes, that is what we announced, and we announced on April 10th that we would release CHF 2.5 billion of capital over three years. And this is linked to the Swiss Solvency Test. So, it means that the Swiss Solvency Test, as you know, is much tougher than the Solvency II test, which means that the global Group solvency in term of Solvency II might be ca. 1% something like this. So, it will be much smaller. But in term of capital and cash, we'll effectively – we'll collect and it will be good for the remittance ratio. We get CHF 2.5 billion which will be upstreamed to the holding company.

Oliver Steel | Deutsche Bank Okay. Thank you very much.

Operator Next question from Andrew Crean from Autonomous. Sir, please go ahead.

Andrew Crean | Autonomous Good morning, Gérald. A couple of questions and a request. Just going back on the de-risking. Do you intend to do more than 20% of the equity portfolio at some point in time? And after two years, I assume you would intend to reload.

Then secondly, on the Personal Lines pricing. I see just over a year ago, rates – Personal Lines rates were rising about 4% and now rising about only 1%. Do you think that has implications for your profitability, i.e., do you have to maintain average claims growing by only 1%?

And then a request. Given the multi-actions you have taken both in XL and the IPO of the US business, would you, at some point in time, be able to give us a sort of pro-forma balance sheet, so that we can work out the tangible equity moves and the impact on debt gearing? It is quite difficult to do from the outside.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Let's start – Andrew, let's start with the de-risking. So, do we have an intention to do more? Not today. So, that means that we consider that it is a good level, and we presently do not have our intention. It does not mean that we could not change our minds, because it depends, of course, on the economic condition. It depends also on the cost of volatility, as you can imagine. Your question, which is good, do you intend to reload at the end of the two years? It will depend on the equity markets. But roughly speaking, what guided me in this decision was just to say that we had a strong growth of the equity market over the last years and it was a way to secure part of the capital gains while being extremely effective in terms of capital management.

The personal pricing. Again, I see your point. And does it mean that we will reduce our profitability? No. It is not our intention and that is the reason why we were in France, we were at minus 4% in term of top line for individual Motor at the beginning of the year. We do not intend to reduce our profitability. And we do not believe because

you know what, I remember, I remind you that we have some objectives in term of at the end of our plan, in term of combined ratio to be between 94% and 95% and we stick to it.

So, we could, from time to time, adjust the top line because we have to keep a certain level of profitability but the price increases is not the only driver because we have also the claims management and we have also fraud and all different drivers that we can use in order fighting fraud, leakage and so on that we can use in order to keep a strong profitability so, no worry on that side.

Your last question, first of all, I just would like to because I take this opportunity, you all read that we intend to launch a mandatory exchangeable, that is what we announced last week. And this mandatory exchangeable, some of you believe that it would be considered as a debt. Indeed, it is a bit technical, but the net present value of the future interest rates that will be paid will be considered as a debt, but the principal will be in minority interest. And that is quite logical because it is mandatory. So, it is not convertible at the option of the holder. It is mandatory redeemable bond into shares, into AXA Equitable Holding shares. So that is the first point.

Second point, at what time we will – I believe that we will wait. Let's wait for the events next week. We should have the pricing of the IPO, but as soon as feasible, of course, we will update you with some elements so that you could have a sound view of our balance sheet and of our debt gearing. So, it will be an update of what we presented on the 5th of March.

Andrew Crean | Autonomous One follow-up question. Is the mandatory convertible part of your Euro 3 billion of debt financing? So the XL, it is not, so there is another Euro 1 billion circulating?

Gérald Harlin | Deputy CEO and Group CFO, AXA No. It is not part of it. It is not part of it. But just – I would like just to tell you that, first of all, the mandatory is a way to reach alternative investors, long-term investors. So, it is one - it is technical, it is a product which is on top of the traditional IPO. But, again, it is not – it won't replace Euro 1 billion of the Euro 3 billion debt. For the time being, it is not planned like this.

Andrew Crean | Autonomous Thank you.

Operator Perfect. So, next question is from Michael Huttner from J.P. Morgan. Sir, please go ahead.

Michael Huttner | J.P. Morgan Fantastic. Thank you so much. And thanks for the guidance on the operating profit contribution to solvency. Just going back to the solvency, my math is probably really wrong, but the figures you have given: 7 points from the debt, 8 points from the hedging. So that is 15. Then, there is a couple of one – there is a minus 3 and a minus 2 linked to the UFR and the change in volatility adjuster and plus 2 or something from the operating profit contribution. So, that gives me a figure of 12 and you actually improved by 16. So, just wondered maybe you can talk about the other bits that would be lovely.

And then, I think the opening question alluded to that and you kind of alluded to that, but I just wondered if you maybe can give a bit more color. So, on the Swiss announcement, you said that the kind of profit impact in the first half of about CHF 400 million. Is that also the gain that you have made on the hedges which will come through, and the gain on the hedges, will they come through in the underlying and in adjusted or in net profit?

And then final question and – you probably think I do not know anything of it, that is probably true. But you know your solvency, so you include the US under equivalence, once you have sold a portion of the US, does that reduce the solvency requirements and the solvency numbers in the US pro-rata, or do you have to – nothing change until you actually reduce to below 50%? Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA Hello, Michael. I will start with the last question first. Yes. It will be pro rata. So, that means that it will be pro rata depending on the percentage that will be sold.

About the solvency, which is your first question, so I said that, in fact, we have three main elements. We have the operational return, operating return, which is a bit more than 2%. Then we have the sub-debt, 7%, and then we have different elements plus which is the hedges that we discussed just before. And we have plus and minuses which, as a whole, makes this block represent 7%. So, it is – the management actions, I would say, correspond to plus 8. And then we have some negatives, but also, we have some small positives coming from various elements. And very often, we are dealing with elements that could be extremely small and will be some small positives. And next is the – your second question was...

Michael Huttner | J.P. Morgan So, my second question was [indiscernible]. You said CHF 400 million is the cost of the Swiss thing in terms of net earnings, and I was wondering the hedging – the gain you have made on the hedges, where it will appear in the profit and loss, which level of earnings? And it is roughly equivalent to this CHF 400 million?

Gérald Harlin | Deputy CEO and Group CFO, AXA I am sorry. I do not understand your question. So...

Michael Huttner | J.P. Morgan Okay. So, let me – so, you know you have hedged 20% of your equity portfolios. So – and equities in Q1 went down, so you have made a profit. And my question is where does the profit appear? And in size, is it roughly of the same order of magnitude as the CHF 400 million cost of the Swiss thing?

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, wait – so long as you are – you buy a put, that's the value of this put which is the increase, so that is the mark-to-market of your put. This mark-to-market will flow in net income. And at the time you will realize it, if the option is in the money, you will leave some intrinsic value, and this intrinsic value should flow through the adjusted earnings. That is the way it will work. I hope I am clear. Tell me if I am not.

Michael Huttner | J.P. Morgan Yeah, yeah. No, that – the accounting is clear. But you made a the profit in Q1 where – and, I mean, I am sorry...

Gérald Harlin | Deputy CEO and Group CFO, AXA No, it is – I do not publish – let's be clear. We do not publish our earnings in Q1.

Michael Huttner | J.P. Morgan No.

Gérald Harlin | Deputy CEO and Group CFO, AXA So, it is two ways, there are plus and minuses, so you have a – but anyway, you can expect – again, you can get expect it to have a – to get it in the – in your earnings net income at the end of H1. So, we will re-discuss it at the end of H1.

Michael Huttner | **J.P. Morgan** Lovely. Thank you very much. Thank you.

Gérald Harlin | **Deputy CEO and Group CFO, AXA** Okay.

Operator So, next question from James Shuck from Citi. Sir, please go ahead.

James Shuck | **Citi Group** Good morning. Thank you for taking my questions. Three for me this morning, please. Firstly, returning to the XL earnings that were reported yesterday, I can appreciate you can't really comment on the direction of travel and you are kind of legally impeded on saying some things but I am just struggling a little bit with the ROE of XL. It is a 9% ROE based on a 95% combined ratio. There is a reasonably high level of debt gearing in that company and there is also quite a high level of investment risk. And the 95% combined ratio from what we have seen from the earnings, any improvement in the underlying is actually being offset by reduction in the volatility. So, could you please clarify for me how you actually see that ROE improving and why you are confident it will?

Secondly, a kind of more general question. Looking at your Life sales in Europe, you seemed to be controlling those very nicely, you have seen a decent growth in the Protection side and in the Health side, particularly in Europe. I am just wondering about how reliant that distribution is on commissions, in particular. Because we have the insurance distribution directive that goes live in October. I am just interested to know how that will play out amongst your tied-agent network.

Final question just around the Solvency II ratio. I kind of return a little bit to Michael's point, let me try to add up all the numbers and what kind of – exactly what's changed in the quarter. I mean, you say that the 4 points is kind of unexplained differences due to small positives kind of being cumulative, but that is bigger than your operating earnings in the period. So, a little bit more color around actually what changed in that Q1. And then, looking forward over the rest of the year, can you anticipate any modeling changes, management actions or any impact from any changes around the EIOPA calibrations on that Solvency II ratio. Thank you very much.

Gérald Harlin | **Deputy CEO and Group CFO, AXA** Okay. So, starting first with your question, first of all, about XL. The ROE, so you can notice the ROE that the published was above 9%. I believe and that is why I said no surprise because it is quite in line with what they expected. I remember that when I presented, beginning of March this acquisition, we said that we should be close to 10%. And I said no surprise because, indeed, they are at the right level, at the level of profitability that, indeed, they were expecting. About the investment, and when I stopped because I go beyond what I am allowed and entitled to tell you but, in investment, I recommend you to go through their disclosures because honestly, their investment portfolio is extremely safe. And I am quite relaxed on that side and I do not consider at all that their portfolio is aggressive at all.

On your second question which is, if I am right, your question about the insurance distribution directive. And we are ready for this. That means that it is something that we are anticipated and we do not have any specific fear on that side and we do not expect that there would be any decline in ourselves following the implementation.

Your last question, so we start from 205%. Starting from a solvency position at 205%, we have an operating return with a rounding plus 3 because, as I said before, it is 2.5 points. So we have the debt, the Euro 2 billion of debt that we issued. That is plus 7. And then we have the hedge which is plus 8. And then we have UFR plus VA which represents minus 2. Indeed, I was wrong when I said answering a previous question, I said minus 2 for UFR and reference portfolio minus 3. It is not additive. I am very sorry for this. So we are between minus 2 and minus 3 for the combined effect of these two. Sorry for that. So that is why you had – I introduce a bit of confusion. And so, if you can, 3 plus 7 plus 8 minus 2, you are 221%. I hope that it is clear now.

James Shuck | Citi Group Okay. And I guess the UFR impacts is so much less than the previous guidance, I suppose, would be the question from that.

Gérald Harlin | Deputy CEO and Group CFO, AXA No, no. I maintain that we are – the combined effect should be minus 3, so that's – no, no. That is in line with what – this is the calculation and this was where we end up.

James Shuck | Citi Group What would be the annual drag from the UFR going forward, please?

Gérald Harlin | Deputy CEO and Group CFO, AXA But the UFR – so long as you have the impact on the UFR, it is one shot. That means that it will be exactly the same for the whole year because you have a minus – so long as you have an effect which is – which has been taken 15 basis points in the first quarter. So, net effect will be the year after, it won't be this year. So, it will be exactly the same.

Andrew Wallace-Barnett | Head of Investor Relations, AXA I think, James, we can put that offline with you. I suspect that probably the UFR estimates that you guys have been doing is probably quite accurate. I think it is the reference portfolio that is bit out of the model. And we will try and see if there is something we can give to everybody to help that to be easier to estimate in the future. And of course, reference portfolio is something that changes annually.

Gérald Harlin | Deputy CEO and Group CFO, AXA Anyway, as explained by Andrew, so that means that we want to be absolutely transparent on this. And if you need any more guidance or explanation, we do not have any – any fear, we will give it.

James Shuck | Citi Group Sure. Okay. And just to be clear, are there any foreseeable modeling changes or management actions, et cetera, for the rest of the year?

Gérald Harlin | Deputy CEO and Group CFO, AXA No. For the time being, I do not expect such type of action.

James Shuck | Citi Group Wonderful. Thank you very much.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Thank you.

Operator Next question from Colm Kelly from UBS. Sir, please go ahead.

Colm Kelly | UBS Thank you. Just one question on new business margin. So, the new business volume margin was flat year-on-year 1Q, and it is lower than the full year despite the continuation of the business mix shift. So, at full year, I know you were confident or under the progression of that margin and the scope for that to continue

to grow. So is the impact we are seeing in 1Q just a bit of short-term seasonality or is there anything within that number that would indicate that the margin expansion is largely complete going forward? And then the reason I ask is obviously the margin expansion has been key to the new business value growth to-date and that is obviously key to maintaining future cash flow growth for that life business. So it is quite an important to understand where the driver of that is going to be going forward. Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, first, we are at 42% which is extremely strong. And when you compare ourselves with our peers, first of all, I would like to say that we are far above our peers in terms of profitability. Of course, it depends on the business mix. You can notice that there are plus and minuses, as I mentioned, roughly, we are flat in France. I do not expect that France will move a lot.

In Europe, we could have some improvements coming progressively from Switzerland because the fact that we will move to a semi-autonomous means that, normally speaking, we should have an increase in the NBV margin in Switzerland. In Italy, you noticed that we made – we benefited from the strong recovery. And so long as we are growing quite fast in Unit-Linked, maybe we could have a slight improvement on that side. So, on Europe, I would say maybe it could go on slightly increasing.

In Asia, I would be cautious. In Asia, I would be cautious because we are already at 62%. In China, we are above 50%, meaning that we will stay most probably at the same level. In Japan, we are around 100%. We can expect to stay at this level. When you are at 100%, it is difficult to do better. And in Hong Kong, we are at 44%. So, it is a balance between growth and profitability that I explained before. So, I believe that we will stay much more at 45% around than ca. 60% like last year. In the other high potential, we are at still 49%. So, we should stay there and maybe we could slightly improve, but that's mostly it.

As far as the US. is concerned, we were at 23%-22% flat and we can expect to remain flat. So, I do not expect, to make it short – we will keep a strong level of NBV margin. We have some elements that could let us believe that we could have some improvement. But I believe that it should be marginal, because we reached a level of profitability which is extremely strong. And as you can imagine, we will try to grow the topline based on this high level of profitability.

Colm Kelly | UBS Okay. That is clear. Thank you.

Operator So next question from Johnny Vo from Goldman Sachs. Sir, please go ahead.

Johnny Vo | Goldman Sachs Yeah. Thank you very much. Just, guys, just in terms of the hedge, where in the Group have you purchased the put options, is it in the holding company? And where is the shareholder exposed to equity in the group, in which entities is it in? Also, the strike of the puts, have you bought at the money or out of the money and how far out of the money? And finally, what is the premium cost for that put option? Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, it is very precise. Hello, Johnny.

Johnny Vo | Goldman Sachs Hi.

Gérald Harlin | Deputy CEO and Group CFO, AXA First, about the hedge, it is in the holding company. Second, the strike, we bought 10% out of the money option. Third question – what's the premium. So, premium is roughly 5% pre-tax for a two year option.

Johnny Vo | Goldman Sachs Okay. So, just – therefore, if the hedge is in the holding company, I guess, it changes, because you released capital, it does not change the remittance profile of your subsidiaries though because each subsidiary...

Gérald Harlin | Deputy CEO and Group CFO, AXA No. Sorry. I see your point. But I would say that, I remind you that the companies we see – with a quite strong, France, for example, there is a strong equity exposure in P&C just like it would be in the holding company. So, that means that, it won't change the remittance ratio of the companies. The only point is it is easier to manage from a practical point of view, because when you have such type of hedges, you have to manage the collateral and so on, and it is easier to do it in the holding company.

Johnny Vo | Goldman Sachs Yeah.

Gérald Harlin | Deputy CEO and Group CFO, AXA No more reason than this one.

Johnny Vo | Goldman Sachs Okay. That is very clear. Thank you.

Operator So, next question from Mr. Michael Huttner from J.P. Morgan. Sir, please go ahead.

Michael Huttner | J.P. Morgan This is a slightly strange question. So, one of your European competitors with a very large US variable annuity business, they have, obviously, hedges for that variable annuity business, which means that when equity markets go up, the hedges lose value and that eats into their reserves, which means that at some stage, the reserve becomes zero and then it becomes a problem, is there anything like that in your business model?

Gérald Harlin | Deputy CEO and Group CFO, AXA Relative to the US, you know yes, we have – I remind you that we are in a situation today where most of the equity in the US are hedged and where we keep an open position on the interest rates, which is relatively good position. Why? Because interest rates are going up so – and they went up. So I am quite happy to have this underlying position. As far as the, you know its the RBC in the US, we have an excellent RBC position, we are above 600%, so I do not have any such fear even if there would be bigger moves on the equity market. So honestly, I do not have such type of fear. You remember that when I presented the plan, it was in November, I said that we would be at least at 500%. We are far above this level, meaning that we have a significant buffer.

Michael Huttner | J.P. Morgan Brilliant. Thank you. Well done. Thank you very much.

Operator We do not have any question for the moment. [Operator Instructions] We have a new question from Mr. Pierre Chedeville from CM-CIC Market Solutions. Sir, please go ahead.

Pierre Chedeville | CM-CIC Yes. Good morning. I have two quick question.

The first question is that I recently read that in Italy, the fact that MPS belongs to a public sector, it could be prohibited to sell insurance products and IVASS, which is a supervisor in Italy, considers it as an anomaly so far. So, what is your view regarding this potential evolution of the regulation that could impede you from recovery in Italy through the BMPS?

And my second question is, how do you see the evolution of the P&C business in France considering the stronger and stronger competition from the banking sector? What, in your view, are the measures that you can take to fight against this new competition? I would see much more aggressive competition in the P&C, not Life, which is an old competition, I would say, but in the P&C business more specifically? Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Relative to your first question, so that is about MPS. Remind you that we renewed our agreement – our bank insurance agreement with MPS for 10 more years. Second, it is a significant – it is a 50/50 partnership, meaning that we participate to the recovery of the bank, which means that it is a strong contributor to the earnings of the bank, and so it is the direct interest of the bank to go on selling it. I remind you at the same time that the shareholder, being the state, it is the interest of the state to keep this bank insurance business because it will be part of the recovery of the bank. So, I have no specific fear on that side. And you notice again that, I remind you, we are very proud to announce that our Unit-Linked business in terms of APE grew by 42% in the first quarter which highlights the strong recovery in the market.

About the P&C business, I believe that it is by different measures. So it is more by segmentation, by favoring some cross-sell, for example, that we have the possibility to grow more the top line of our P&C business in France. But, you know again, Personal Non-Motor, we were at zero. We can expect to recover with more Household insurance. And on Personal Motor, as I said, answering the previous question, I believe that minus 4 is very low and that we will do better in the rest of the year. So, when we have different measures, but – which are additional incentives that are given to the networks and some incentive also to sell some combined product and to cross-sell products between Motor and non-Motor.

Pierre Chedeville | CM-CIC Okay, thank you.

Operator Okay. So, next question is from Mark Cathcart from Jefferies. Sir, please go ahead.

Mark Cathcart | Jefferies Yeah. Hi. It is Mark Cathcart from Jefferies. I think you mentioned that post XL, your gearing ratio will be somewhere between 31% and 32%. If I take the convertible that you are raising of USD 750 million, that is worth about 1 point on that debt ratio. So, can you confirm that the debt ratio guidance is still within that 31% to 32% range, but likely at 32% because of the convertible or is there any risk that it could go above 32%? Thank you.

Gérald Harlin | Deputy CEO and Group CFO, AXA No, I consider that we have no risks to go above this level. Second, Mark, I confirm that this mandatory convertible will not be a part, only a small part of it will be considered as debt, great majority will be considered as a minority interest. And, again, it is not a debt. It would be a debt, if it would be up to the holder to decide whether they will convert or not. So long as it is a mandatory, it means that whatever happens, after a while, you will convert this debt into equity. So, that is quite logical that it is not

considered as debt. And so that is the point. So, no, to make it clear, I have no fear that we would go above the guidance that we gave you. So, no, not at all, not at all.

Mark Cathcart | Jefferies Okay. Thank you.

Andrew Wallace-Barnett | Head of Investor Relations, AXA Mark, the MEB³ is roughly neutral for the gearing ratio.

Mark Cathcart | Jefferies Okay. Thank you.

Operator Okay. Next question from Michael, Michael Huttner from J.P. Morgan. Sir, please go ahead.

Michael Huttner | J.P. Morgan Sorry. Last question, in Germany, you had this lovely growth in Personal Motor and Personal Non-Motor of 3% and 4%. And is this mainly price or is this a mainly volume, please? And just to gain a feel for where pricing is moving, I guess, so you said pricing in France up 1%, and I just wondered in Germany?

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Maybe you can – we can go to page 14, Michael, of the press release and you will see that on Personal line, we had 1.2% price increase which is more or less in line with our own expectations. So, if your question is, do you expect – still expect to have such type of price increase, yes, I believe that for Motor, it is a maximum. For other lines, we have much more flexibility. But again, I repeat what I said, we have – and again, I am not at all worried by the global effect on our P&C business. I repeat what I said. But in France, yes, we have a situation where the Motor business, individual Motor business is under pressure, under competitive pressure and coming mostly from the bank insurer but also from the mutuals. And I remind you and I repeat that the average combined ratio in France should be at ca. 105%. So, it is the point. About Germany, the price effect – the average price effect in Personal lines for Germany is 2.4%, so we still – there are other at countries where we keep a stronger price effect, and at that at the same time in Germany, we have a volume effect of plus 1%. In Switzerland, we have a volume of plus 1%; Spain, 1%; Italy, 1.1%. So, we have a specific case in France, but honestly, in most of the other countries, it is not only driven by the price effect, it is also the volume effect which is positive.

Michael Huttner | J.P. Morgan Oh. That is a brilliant answer. Thank you so much. Thank you.

Operator So, next question from Andrew Sinclair from Bank of America Merrill Lynch. Sir, please go ahead.

Andrew Sinclair | Bank of America Merrill Lynch Sorry. Just one final question from me. Just wondering if you could confirm for the mandatory convertible, what are the terms under which AXA can compel conversion prior to maturity of the bond? Thanks.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. Of course, Andrew, I cannot answer your questions because it is a point, you know that I cannot disclose for the time being, and what I could say that you can see, and the best way for you is to look at the other mandatory convertibles that have been issued, and you will see

³ MEB stands for mandatory exchangeable bond.

what are the common financial features, so that you will see how it works but it is not very complex. You know, it is a mandatory convertible. At the end, it is just a loan.

And after you have a mandatory conversion, and this mandatory conversion, you have a flexibility in the number of share that you give because if there is a price appreciation, then the holder will get less shares because there is value appreciation. So, in other terms, it is just like you would buy a call option that is something like this and it is – that is mostly it. But honestly, my advice would be for you to go through a documentation of other types of mandatory like this. It is extremely simple. The fact that it interest investors that when you are long-term investors, when you are sure that you will stay a long period of time, it could be interesting because, of course, in exchange for this option, you have a higher return and you have a coupon which is higher.

Andrew Sinclair | Bank of America Merrill Lynch Okay. So, that is fairly standard terms then. Understand. Thanks.

Operator We do not have any more questions. [Operator Instructions]. We do not have any more question. Back to you for the conclusion, sir.

Gérald Harlin | Deputy CEO and Group CFO, AXA Okay. So, I thank you a lot for this call. So, I was happy to have this exchange with you and speak to you soon. Thank you.

Andrew Wallace-Barnett | Head of Investor Relations, AXA Have a good day.

Gérald Harlin | Deputy CEO and Group CFO, AXA Have a good day. Bye bye.

*** END OF THE TRANSCRIPT ***